Real-World data shows Lenvatinib's promise for advanced liver cancer
NCT ID NCT07298538
First seen Jan 07, 2026 · Last updated Jun 05, 2026 · Updated 26 times
Summary
This study looked back at the medical records of 800 adults with liver cancer that could not be removed by surgery. All patients were treated with lenvatinib, a targeted therapy, at six hospitals. The goal was to see how long patients lived and how well the treatment worked in everyday practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, 300060, China
Conditions
Explore the condition pages connected to this study.